News
Article
Author(s):
The program will deliver a range of high-quality access and affordability services for retina specialists.
Harrow, one of the leading eye care pharmaceutical companies in North America, announced the launch of its “Harrow Cares” program in partnership with Cencora, a global leader in pharmaceutical solutions. The program will deliver a range of high-quality access and affordability services, strengthening support for retina specialists, their staff and patients.
Harrow Cares will also provide a patient support services hub to ensure seamless enrollment, quick access to therapy and personalized support. Through this element of the program, it will enable retina providers to confidently use practices, such as IHEEZO and TRIESENCE, in their practices.
“We are thrilled to collaborate with Cencora on the launch of our ‘Harrow Cares’ program,” Mark L. Baum, chief executive officer of Harrow, said. “This partnership reflects our shared commitment to addressing one of the most critical challenges in healthcare – ensuring that life‑changing medications are both accessible and affordable. The Harrow Cares initiative underscores Harrow’s unwavering dedication to creating meaningful solutions that empower patients, reduce barriers to treatment, and drive better health outcomes.”
With Cencora, the company will also provide services ranging from real-time benefit verifications to flexible affordability options and product assurance programs. Baum believes the partnership will also allow Harrow to grow in popularity in the US retina market.
“Furthermore, this milestone highlights our strategic focus on expanding and solidifying Harrow’s presence in the US retina market, a key area of growth and innovation for our company,” Baum said. “We look forward to working closely with Cencora to advance innovative ophthalmic solutions that enhance patient care and improve access to vital treatments.”
Other key features of the Harrow Cares program include streamlined enrollment, rapid access to therapy and assurance and ongoing support.